| Create a Free Account or Sign In to connect and share in green living and alternative energy forum discussions. |
0
Jnj's $32 Billion Bid For Actelion
Views: 607
Actelion makes therapies to treat,
. . . pulmonary arterial hypertension (PAH),
. . . a disease characterized by,
. . . high blood pressure between the heart, and lungs.
Wells Fargo Securities believes,
. . . Johnson & Johnson may buy Actelion for
. . . $32 billion.
“J&J, of all the big pharmas, is the best one for Actelion,’’
. . . said John Rountree, managing partner at Novasecta Ltd.,
. . . a pharmaceutical consulting firm in London.
J&J would give the Swiss company access to the U.S. capital market, and
. . . may allow Actelion to maintain at least some independence, he said.
“They perhaps might be more hands off,
. . . than some other potential acquirers,’’ he said.
12-23-2016 Source: Johnson & Johnson's $32 Billion for Actelion Independence
. . . pulmonary arterial hypertension (PAH),
. . . a disease characterized by,
. . . high blood pressure between the heart, and lungs.
Wells Fargo Securities believes,
. . . Johnson & Johnson may buy Actelion for
. . . $32 billion.
“J&J, of all the big pharmas, is the best one for Actelion,’’
. . . said John Rountree, managing partner at Novasecta Ltd.,
. . . a pharmaceutical consulting firm in London.
J&J would give the Swiss company access to the U.S. capital market, and
. . . may allow Actelion to maintain at least some independence, he said.
“They perhaps might be more hands off,
. . . than some other potential acquirers,’’ he said.
12-23-2016 Source: Johnson & Johnson's $32 Billion for Actelion Independence
